争鸣
慢性气道疾病的分类诊断如何更好地适应个体化治疗需求
王颖
黄克武
作者及单位信息
·
DOI: 10.3760/cma.j.cn112147-20220211-00108
845
201
0
0
6
1
PDF下载
APP内阅读
摘要

传统诊断定义下的慢性阻塞性肺疾病(简称慢阻肺)与支气管哮喘(简称哮喘)被认为是两类不同的疾病。而事实上,慢阻肺与哮喘是处于具有连续疾病特征的慢性气道疾病的两个极端表型,其症状、发病机制呈连续性,且目前治疗手段趋于类同。这种传统的疾病分类范式已落后于目前对慢性气道疾病的认知,限制了对慢性气道疾病发病机制的深入探索,滞缓了新的干预靶点的开发以及个体化治疗。因此,我们需要考虑对慢性气道疾病重新定义或分类,积极开展以临床问题为导向的基础-临床转化研究,充分利用现已识别的可治疗特征对患者进行再分类,并进行个体化的治疗干预。

引用本文

王颖,黄克武. 慢性气道疾病的分类诊断如何更好地适应个体化治疗需求[J]. 中华结核和呼吸杂志,2022,45(07):712-715.

DOI:10.3760/cma.j.cn112147-20220211-00108

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价
慢性阻塞性肺疾病(简称慢阻肺)和支气管哮喘(简称哮喘)是严重危害公众健康的常见慢性气道疾病,全球约有6亿患者,2015年,全球约320万人死于慢阻肺,40万人死于哮喘 1。在我国,中国肺部健康研究(CPH)结果显示,我国20岁以上人群的慢阻肺的患病率为8.6%,哮喘的患病率为4.2%,按照2015年的全国人口普查数据推算,中国有近1亿慢阻肺患者 2,20岁以上成人哮喘患者4 570万 3
试读结束,您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Collaborators GBDCRD . Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet Respir Med, 2017,5(9):691-706. DOI: 10.1016/S2213-2600(17)30293-X .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Wang C , Xu J , Yang L ,et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study[J]. Lancet, 2018,391(10131):1706-1717. DOI: 10.1016/S0140-6736(18)30841-9 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Huang K , Yang T , Xu J ,et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study[J]. Lancet, 2019,394(10196):407-418. DOI: 10.1016/S0140-6736(19)31147-X .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Global Initiative for Asthma. Global strategy for Asthma Management and Prevention[EB/OL]. Updated 2021. [ 2022-01-20]. https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf.
返回引文位置Google Scholar
百度学术
万方数据
[5]
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease[EB/OL]. Updated 2022. [ 2022-01-20]. https://goldcopd.org/2022-gold-reports-2/.
返回引文位置Google Scholar
百度学术
万方数据
[6]
Bateman ED , Reddel HK , van Zyl-Smit RN ,et al. The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases?[J]. Lancet Respir Med, 2015,3(9):719-728. DOI: 10.1016/S2213-2600(15)00254-4 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Ding B , DiBonaventura M , Karlsson N ,et al. Asthma-chronic obstructive pulmonary disease overlap syndrome in the urban Chinese population: prevalence and disease burden using the 2010, 2012, and 2013 China National Health and Wellness Surveys[J]. Int J Chron Obstruct Pulmon Dis, 2016,11:1139-1150. DOI: 10.2147/COPD.S103873 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Cazzola M , Rogliani P . Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome?[J]. J Allergy Clin Immunol, 2016,138(4):977-983. DOI: 10.1016/j.jaci.2016.04.028 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Caillaud D , Chanez P , Escamilla R ,et al. Asthma-COPD overlap syndrome (ACOS) vs ′pure′ COPD: a distinct phenotype?[J]. Allergy, 2017,72(1):137-145. DOI: 10.1111/all.13004 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Pavord ID , Chanez P , Criner GJ ,et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease[J]. N Engl J Med, 2017,377(17):1613-1629. DOI: 10.1056/NEJMoa1708208 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Criner GJ , Celli BR , Singh D ,et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies[J]. Lancet Respir Med, 2020,8(2):158-170. DOI: 10.1016/S2213-2600(19)30338-8 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Bateman ED , Reddel HK , O′Byrne PM ,et al. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma[J]. N Engl J Med, 2018,378(20):1877-1887. DOI: 10.1056/NEJMoa1715275 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Brightling CE , Nair P , Cousins DJ ,et al. Risankizumab in Severe Asthma-A Phase 2a, Placebo-Controlled Trial[J]. N Engl J Med, 2021,385(18):1669-1679. DOI: 10.1056/NEJMoa2030880 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Lipson DA , Barnhart F , Brealey N ,et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD[J]. N Engl J Med, 2018,378(18):1671-1680. DOI: 10.1056/NEJMoa1713901 .
返回引文位置Google Scholar
百度学术
万方数据
[15]
Vogelmeier C , Hederer B , Glaab T ,et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD[J]. N Engl J Med, 2011,364(12):1093-1103. DOI: 10.1056/NEJMoa1008378 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Beasley R , Weatherall M , Travers J ,et al. Time to define the disorders of the syndrome of COPD[J]. Lancet, 2009,374(9691):670-672. DOI: 10.1016/S0140-6736(09)61541-5 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Fingleton J , Huang K , Weatherall M ,et al. Phenotypes of symptomatic airways disease in China and New Zealand[J]. Eur Respir J, 2017,50(6):1700957. DOI: 10.1183/13993003.00957-2017 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
Martinez FD , Vercelli D . Asthma[J]. Lancet, 2013,382(9901):1360-1372. DOI: 10.1016/S0140-6736(13)61536-6 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Vestbo J , Hurd SS , Agusti AG ,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary[J]. Am J Respir Crit Care Med, 2013,187(4):347-365. DOI: 10.1164/rccm.201204-0596PP .
返回引文位置Google Scholar
百度学术
万方数据
[20]
Busse W , Corren J , Lanier BQ ,et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma[J]. J Allergy Clin Immunol, 2001,108(2):184-190. DOI: 10.1067/mai.2001.117880 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
Bel EH , Wenzel SE , Thompson PJ ,et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma[J]. N Engl J Med, 2014,371(13):1189-1197. DOI: 10.1056/NEJMoa1403291 .
返回引文位置Google Scholar
百度学术
万方数据
[22]
Bleecker ER , FitzGerald JM , Chanez P ,et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial[J]. Lancet, 2016,388(10056):2115-2127. DOI: 10.1016/S0140-6736(16)31324-1 .
返回引文位置Google Scholar
百度学术
万方数据
[23]
Pavord ID , Lettis S , Locantore N ,et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD[J]. Thorax, 2016,71(2):118-125. DOI: 10.1136/thoraxjnl-2015-207021 .
返回引文位置Google Scholar
百度学术
万方数据
[24]
中华医学会呼吸病学分会肺栓塞与肺血管病学组. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志, 2021,101(1):11-51. DOI: 10.3760/cma.j.cn112137-20201008-02778 .
返回引文位置Google Scholar
百度学术
万方数据
[25]
Terl M , Sedlak V , Cap P ,et al. Asthma management: A new phenotype-based approach using presence of eosinophilia and allergy[J]. Allergy, 2017,72(9):1279-1287. DOI: 10.1111/all.13165 .
返回引文位置Google Scholar
百度学术
万方数据
[26]
Miravitlles M , Calle M , Molina J ,et al. Spanish COPD Guidelines (GesEPOC) 2021: Updated Pharmacological treatment of stable COPD[J]. Arch Bronconeumol (Engl Ed), 2022,58(1):69-81. DOI: 10.1016/j.arbres.2021.03.005 .
返回引文位置Google Scholar
百度学术
万方数据
[27]
Tashkin DP , Celli B , Decramer M ,et al. Bronchodilator responsiveness in patients with COPD[J]. Eur Respir J, 2008,31(4):742-750. DOI: 10.1183/09031936.00129607 .
返回引文位置Google Scholar
百度学术
万方数据
[28]
Reid DW , Wen Y , Johns DP ,et al. Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related[J]. Respirology, 2008,13(6):799-809. DOI: 10.1111/j.1440-1843.2008.01380.x .
返回引文位置Google Scholar
百度学术
万方数据
[29]
Agusti A , Bel E , Thomas M ,et al. Treatable traits: toward precision medicine of chronic airway diseases[J]. Eur Respir J, 2016,47(2):410-419. DOI: 10.1183/13993003.01359-2015 .
返回引文位置Google Scholar
百度学术
万方数据
[30]
McDonald VM , Fingleton J , Agusti A ,et al. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report[J]. Eur Respir J, 2019,53(5):1802058. DOI: 10.1183/13993003.02058-2018 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
黄克武,Email: mocdef.6ab21gnauhuwek
B

王颖, 黄克武. 慢性气道疾病的分类诊断如何更好地适应个体化治疗需求[J]. 中华结核和呼吸杂志, 2022, 45(7): 712-715. DOI: 10.3760/cma.j.cn112147-20220211-00108.

C
所有作者声明无利益冲突
D
国家自然科学基金 (81870032)
北京市医院管理中心“登峰”人才培养项目 (DFL20190301)
评论 (0条)
注册
登录
时间排序
暂无评论,发表第一条评论抢沙发
MedAI助手(体验版)
文档即答
智问智答
机器翻译
回答内容由人工智能生成,我社无法保证其准确性和完整性,该生成内容不代表我们的态度或观点,仅供参考。
生成快照
文献快照

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持:

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号